Biomarker-Driven Initial Systemic Therapy Enabling Curative-Intent Treatment in Non-Metastatic Unresectable Salivary Duct Carcinoma: A Multi-Institutional Retrospective Study.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42538489.
- Also identified by DOI 10.1002/hed.70416.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Optimal treatment for non-metastatic unresectable salivary duct carcinoma (SDC) remains unclear. We compared outcomes of upfront biomarker-targeted systemic therapy and radiotherapy. We retrospectively analyzed the Joint SDC Study Group registry. Thirty-one patients with centrally confirmed non-metastatic unresectable SDC were classified by initial treatment (radiotherapy or systemic therapy). Systemic therapy included trastuzumab plus docetaxel, combined androgen blockade, or chemotherapy. Progression-free survival (PFS) and overall survival (OS) were analyzed. Systemic therapy showed better PFS than radiotherapy (3-year PFS 47.6% vs. 30.0%, p = 0.031) without OS difference. Trastuzumab plus docetaxel showed the highest response rate (75%) and enabled curative-intent treatment in all cases, with the best PFS (3-year 87.5%, p = 0.012). Given the retrospective design and limited sample size, these findings should be regarded as hypothesis-generating. An upfront trastuzumab-based therapy followed by curative-intent treatment may be a promising option for selected patients with HER2-positive unresectable SDC.